Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory
Source: SeekingAlpha
2026-03-09 11:28:03 ET
Overview
Intellia Therapeutics’ stock ( NTLA ) is flat since my “ Sell ” rating earlier this year. This is a company advancing its in vivo gene therapies: mainly for ATTR and HAE. I’ve expressed caution in the past. Both ATTR-CM and HAE are crowded spaces and peer gene therapy launches, like CRISPR’s ( CRSP )/Vertex's ( VRTX ) ex vivo CASGEVY in SCD and TDT, have disappointed. Throw in nearly $400M in cash burn (cash from operations) in FY25 and things can become unattractive quickly....
Read the full article on Seeking Alpha
For further details see:
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory
Intellia Therapeutics Inc.
NASDAQ: NTLA
NTLA Trading
-1.05% G/L:
$13.8339 Last:
1,221,299 Volume:
$13.64 Open:
NTLA Latest News
March 03, 2026 07:30:00 am
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
March 02, 2026 07:30:00 am
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
NTLA Stock Data
$1,420,074,893
112,239,198
1.45%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
